An Evaluation of the Utility of Big Data to Supplement Cancer Treatment Information: Linkage Between IQVIA Pharmacy Database and the Surveillance, Epidemiology, and End Results Program. Issue 55 (15th May 2020)

• Record Type: Journal Article
• Authors: Tran, Quyen; Warren, Joan L; Barrett, Michael J; Annett, Dave; Marth, Melissa; Cress, Rosemary D; Deapen, Dennis; Glaser, Sally L; Gomez, Scarlett L; Schwartz, Stephen M; Li, Christopher I; Wu, Xiao-Cheng; Enewold, Lindsey; Harlan, Linda C; Rivera, Donna R; Winn, Deborah M; Penberthy, Lynne; Cronin, Kathleen A
• Is Part Of: Journal of the National Cancer Institute. Issue 55(2020)
• Page Start: 72
• Page End: 81
• Publication Date: 2020-05-15
• Subjects: Cancer -- Periodicals; Cancer -- Congresses; 616.994
• DOI: 10.1093/jncimonographs/lgz036
• Languages: English
• ISSNs: 1052-6773

Abstract

Abstract: Oral anticancer medications (OAMs) are increasingly utilized. We evaluated the representativeness and completeness of IQVIA, a large aggregator of pharmacy data, for breast cancer, colon cancer, chronic myeloid leukemia, and myeloma cases diagnosed in six Surveillance, Epidemiology, and End Results Program (SEER) registries between 2007 and 2011. Patient's SEER and SEER-Medicare data were linked and compared with IQVIA pharmacy data from 2006 to 2012 for specific OAMs. Overall, 67.6% of SEER cases had a pharmacy claim in IQVIA during the treatment assessment window. This varied by location, race and ethnicity, and insurance status. IQVIA consistently identified fewer cases who received an OAM of interest than SEER-Medicare. The difference was least pronounced for breast cancer agents and most pronounced for myeloma agents. The IQVIA pharmacy database included a large portion of persons in the SEER areas. Future studies should assess receipt of OAMs for other cancer sites and in different SEER registries.